“…All probands were exome or genome sequenced (triobased whole-exome sequencing in families I and III; singleton whole-genome sequencing in family II; duo wholegenome sequencing in family IV). Target-enrichment, high-throughput sequencing and variant screenings were performed using established procedures 4,5,7,[9][10][11][12] (for details, see Supporting Information Methods). In brief, libraries were generated using SureSelect Human All Exon V6 (families I and III), KAPA HyperPrep (family II), or NEB-Next Ultra II (family IV) kits, and sequenced on Illumina platforms.…”